NewAmsterdam Pharma Co N.V. - 10-Q Summary (Q2 2025)
Business Context and Reporting Period
NewAmsterdam Pharma Company N.V. is a late-stage biopharmaceutical company focused on developing obicetrapib, an oral CETP inhibitor for lowering LDL-C. The company operates under a single segment and relies on a license agreement with Menarini for revenue in European territories. This report covers the quarterly period ended June 30, 2025.
Key Financial Metrics
| Metric (in thousands USD) | Q2 2025 (3 Months) | Q2 2024 (3 Months) | YTD 2025 (6 Months) | YTD 2024 (6 Months) |
|---|---|---|---|---|
| Revenue | $19,145 | $2,279 | $22,123 | $3,680 |
| Net Loss | $(17,364) | $(39,007) | $(56,891) | $(132,774) |
| Operating Loss | $(35,635) | $(52,575) | $(104,560) | $(108,057) |
| Cash & Cash Equivalents | $563,864 (as of June 30, 2025) | |||
| Total Marketable Securities | $219,470 (as of June 30, 2025) | |||
| Total Liquidity | $783,334 (as of June 30, 2025) | |||
| Net Cash Used in Operating Activities | N/A | $(74,139) | $(108,581) |
Material Changes vs. Prior Period
- Revenue Surge: Revenue increased 740% QoQ and 501% YTD, driven primarily by the recognition of $16.1 million in revenue related to the second installment of development cost contributions under the Menarini License. The R&D performance obligation was deemed fully satisfied.
- Reduced Net Loss: Net loss improved significantly to $17.4 million for Q2 2025 from $39.0 million in Q2 2024. This improvement was aided by a $8.6 million foreign exchange gain and a $2.6 million gain from fair value changes in warrants.
- Expense Trends: R&D expenses decreased 28% QoQ due to the completion of several Phase 3 trials in late 2024. Conversely, SG&A expenses increased 65% QoQ, driven by personnel costs (including share-based compensation) and marketing preparations for a potential commercial launch.
- Balance Sheet: Total current liabilities decreased from $106.9 million to $36.5 million, largely due to the full settlement of the $44.8 million derivative earnout liability in March 2025 via the issuance of 1.74 million ordinary shares.
Guidance, Outlook, and Risks
- Clinical Developments: The company announced positive Alzheimer's Disease (AD) biomarker data from the BROADWAY trial, showing statistically significant reductions in p-tau217, a key AD pathology biomarker, particularly in ApoE4 carriers.
- Liquidity Outlook: With approximately $783 million in cash and marketable securities, management believes it has sufficient liquidity to fund operations for the foreseeable future. No new equity sales occurred under the At-the-Market offering in the first half of 2025.
- Regulatory & Commercial: The company is preparing regulatory applications for obicetrapib. Future revenue remains contingent on regulatory approval and the success of the Menarini partnership in Europe.
- Risks: Key risks include the uncertainty of clinical trial outcomes, dependence on the Menarini license for revenue, potential impacts of U.S. tariff policies on supply chains, and the volatility of warrant liabilities affecting net income.
Investor Verification Checklist
- Verify the sustainability of the $16.1 million revenue recognition from the Menarini license and the timing of future milestone payments.
- Confirm the status and timeline of the PREVAIL cardiovascular outcomes trial (CVOT) to validate the MACE reduction signal observed in BROADWAY.
- Monitor the impact of foreign exchange fluctuations on reported earnings, given the significant Euro exposure ($124.3 million net exposure).
- Assess the burn rate relative to the $783 million cash position to determine runway for the upcoming regulatory submissions.
- Review the terms of the derivative warrant liabilities ($20.9 million) and their potential impact on future earnings volatility.